Accueil   Diary - News   All news Nosopharm raises €2.4 million ($2.6M) to develop a novel antibiotic class

Nosopharm raises €2.4 million ($2.6M) to develop a novel antibiotic class

Lyon, France, March 28, 2017 - Nosopharm, a biotechnology company specialized in the research and development of new antimicrobial molecules, today announces a financing round of €2.4 million ($2.6M), with Auriga Partners, Kreaxi and Alto Invest joining the company’s long-standing shareholders.

 

 

The funds raised will allow Nosopharm to accelerate the regulatory preclinical development of its first antibiotic molecule, NOSO-95179, which targets Enterobacteriaceae, a priority pathogen according to the WHO1 . First-in-man studies are expected to start in 2019.

 

 

Read the press release 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree